Eun Ju Cho

Dr. Eun Ju Cho

Seoul National University Hospital
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
JBJae Seok Bae
Jae Seok Bae
DLDong Ho Lee
Dong Ho Lee
JLJae Young Lee
Jae Young Lee
HKHaeryoung Kim
Haeryoung Kim
SYSu Jong Yu
Su Jong Yu
BCByung Ihn Choi
Byung Ihn Choi

1 April 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DLDong Ho Lee
Dong Ho Lee
ECEun Ju Cho
Eun Ju Cho
JBJae Seok Bae
Jae Seok Bae
JLJae Young Lee
Jae Young Lee
SYSu Jong Yu
Su Jong Yu
BCByung Ihn Choi
Byung Ihn Choi

10 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
HWHyun Goo Woo
Hyun Goo Woo
JCJi-Hye Choi
Ji-Hye Choi
SYSarah Yoon
Sarah Yoon
BJByul A. Jee
Byul A. Jee
ECEun Ju Cho
Eun Ju Cho
YKYoon Jun Kim
Yoon Jun Kim
Hepatocellular carcinoma harbors numerous genomic and epigenomic aberrations of DNA copy numbers and DNA methylation. Transcriptomic deregulation by these aberrations plays key driver roles in heterogeneous progression of cancers. Here, we profile DNA copy numbers, DNA methylation, and messenger RNA expression levels from 64 cases of hepatocellular carcinoma specimens. We find that the frequencies of the aberrancies of the DNA copy-number-correlated (CNVcor) expression genes and the methylation-correlated expression (METcor) genes are co-regulated significantly. Multi-omics integration of the CNVcor and METcor genes reveal three prognostic subtypes of hepatocellular carcinoma, which can be validated by an independent data. The most aggressive subtype expressing stemness genes has frequent BAP1 mutations, implying its pivotal role in the aggressive tumor progression. In conclusion, our integrative analysis of genomic and epigenomic regulation provides new insights on the multi-layered pathobiology of hepatocellular carcinoma, which might be helpful in developing precision management for hepatocellular carcinoma patients.

1 December 2015 in Medicine
Verified
Journal Article
Open access
SYSu Jong Yu
Su Jong Yu
KKKim Kim
Kim Kim
DKDonghee Kim
Donghee Kim
JYJung-Hwan Yoon
Jung-Hwan Yoon
KLKyoung Bun Lee
Kyoung Bun Lee
CKChung Yong Kim
Chung Yong Kim
Nonalcoholic fatty liver disease (NAFLD) is associated with visceral obesity. However, the association between visceral adipose tissue (VAT) area and fibrosis in NAFLD patients has not been completely established. This study was aimed to determine the relationship between the computed tomography-measured VAT area and significant fibrosis in NAFLD patients. A total of 324 NAFLD patients and 132 controls were evaluated by liver biopsy. NAFLD was diagnosed based on histological examinations and alcohol consumption <20 g/day. The NAFLD patients showed a higher age and gender-adjusted VAT area than the control group (86.1 ± 2.3 vs 56.7 ± 3.7, P < 0.001). The VAT area increased across the control, NAFLD without significant fibrosis, and NAFLD with significant fibrosis groups (54.9 ± 3.5, 80.6 ± 2.4, and 123.4 ± 6.4, P < 0.001). This association persisted after adjusting for multiple confounders (P for trend = 0.028). A multivariate regression analysis demonstrated the VAT area was independently associated with NAFLD with significant fibrosis (F2-F4) (odds ratio [OR] 1.21 95% confidence interval [CI] 1.07-1.37 per 10 cm(2) increase of VAT area; OR 2.62 [per 1 - standard deviation (SD)] 95% CI 1.41-4.86). Moreover, a multivariate logistic regression analysis revealed the VAT area was independently associated with nonalcoholic steatohepatitis (NASH) in NAFLD (OR 1.17 95% CI 1.05-1.32 per 10 cm increase of VAT area; OR 2.21 [per 1 - SD] 95% CI 1.25-3.89). Increased VAT area is independently associated with NASH or significant fibrosis and VAT might be a central target for lifestyle modifications in NAFLD patients.

25 September 2017 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
ECEun Ju Cho
Eun Ju Cho
SKSung Eun Kim
Sung Eun Kim
KSKi Tae Suk
Ki Tae Suk
JAJihyun An
Jihyun An
SJSoung Won Jeong
Soung Won Jeong
YKYoon Jun Kim
Yoon Jun Kim
Hepatitis B virus (HBV) infection is the most common cause of chronic liver diseases in Korea. After the introduction of the universal HBV vaccination program, the prevalence of hepatitis B surface antigen was markedly reduced, and Korea is now classified as an area of intermediate endemicity for HBV. However, there are still hurdles for elimination of hepatitis B, such as immunoprophylaxis failure against vertical transmission, occurrence of acute hepatitis B among peoples who did not have vaccination at younger age, and rapid increase of immigrant populations from HBV endemic areas. To achieve the World Health Organization goal of viral hepatitis elimination by 2030 in Korea, we suggest comprehensive policies for more effective control of hepatitis B as following: i) insurance coverage for antiviral prophylaxis in mothers with high viremia, ii) screening for hepatitis B seromarkers and catch-up HBV vaccinations of susceptible persons with hepatitis B, iii) establishment of an independent 'viral hepatitis sector' in Centers for Disease Control & Prevention to organize and execute comprehensive strategy for management of viral hepatitis, iv) encourage of management of HBV infection in immigrant populations, v) national campaign to promote awareness of hepatitis B.

24 August 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SKSeong Hee Kang
Seong Hee Kang
YLYun Bin Lee
Yun Bin Lee
JLJeong-Hoon Lee
Jeong-Hoon Lee
JNJ. Y. Nam
J. Y. Nam
YCY. Chang
Y. Chang
JYJ.‐H. Yoon
J.‐H. Yoon